Fujifilm Diosynth Biotechnologies and SHL Medical Partner to Address Growing Demand for Autoinjector Medicines

Fujifilm Diosynth Biotechnologies will significantly enhance its finished goods autoinjector services through a strategic partnership with SHL Medical. This non-exclusive agreement, part of SHL’s Alliance Management Program, aims to streamline processes and boost efficiency for pharmaceutical and biotech companies, offering pre-validated final assembly services for Molly autoinjectors. With an increased capacity of up to 30 million units per year starting early 2025, the collaboration seeks to provide faster development, streamlined communications, reduced supply chain risks, and a more sustainable manufacturing footprint.